Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phag... von Naicker, Serika D, Feerick, Claire L, Lynch, Kevin, Swan, Dawn, McEllistrim, Cian, Henderson, Robert, Leonard, Niamh A, Treacy, Oliver, Natoni, Alessandro, Rigalou, Athina, Cabral, Joana, Chiu, Christopher, Sasser, Kate, Ritter, Thomas, O'Dwyer, Michael, Ryan, Aideen E

Volltext

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP von Naicker, Serika, Rigalou, Athina, McEllistrim, Cian, Natoni, Alessandro, Chiu, Christopher, Sasser, Kate, Ryan, Aideen, O'Dwyer, Michael

Volltext

Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophag... von Rigalou, Athina, Ryan, Aideen, Natoni, Alessandro, Chiu, Christopher, Sasser, Kate, O'Dwyer, Michael E

Volltext